The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Increased capability to produce medicines for challenging diseases including cancer
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Propranolol LA is a generic equivalent of Inderal LA
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
DKSH has further fortified its strategic partnership with Biolin Scientific, a globally recognized pioneer in surface science instrumentation, across nine key markets in the APAC region
JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Subscribe To Our Newsletter & Stay Updated
